Healthcare Wrap: Imugene Soars, Vitasora Rallies as Biotech Price Swings Persist

• Imugene jumped 36.84% after early trial data showed an 81% response rate in a blood cancer group.
• Vitasora rose 27.27% as its new patient record system cut software costs and lifted enrolments.
• Takeover activity stayed active, with SDI moving closer to a A$1.40 a share cash deal.
• Large contract wins helped Pro Medicus, Mach7 and EBR strengthen their US hospital exposure.